T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia

Gain-of-function mutations of FLT3 (FLT3-ITD), comprises up to 30% of normal karyotype acute myeloid leukemia (AML) and is associated with an adverse prognosis. Current FLT3 kinase inhibitors have been tested extensively, but have not yet resulted in a survival benefit and novel therapies are awaite...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Alachkar, Houda, Mutonga, Martin, Malnassy, Gregory, Park, Jae-Hyun, Fulton, Noreen, Woods, Alex, Meng, Liping, Kline, Justin, Raca, Gordana, Odenike, Olatoyosi, Takamatsu, Naofumi, Miyamoto, Takashi, Matsuo, Yo, Stock, Wendy, Nakamura, Yusuke
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2015
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741775/
https://ncbi.nlm.nih.gov/pubmed/26450903
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg